Utility of galactomannan diagnostic assay in rhino-orbito-cerebral mycosis in COVID-19 patients

Indian J Med Microbiol. 2024 Mar-Apr:48:100557. doi: 10.1016/j.ijmmb.2024.100557. Epub 2024 Mar 8.

Abstract

An increasing number of fungal infections were reported post COVID-19 and many of them were caused by fungi of mixed aetiologies. This study was carried out to assess the utility of serum galactomannan (GM) assay in establishing the etiology of acute rhino-orbito-cerebral mycosis caused by Aspergillus spp. Two serum samples were obtained from 41 suspected post COVID-19 rhino-orbito-cerebral mycosis patients to perform GM assay. Serum GM assay was positive in 68.7% of the cases of proven aspergillosis at cut off OD = 1.0. Serum GM assay can be used as a supplementary test in the diagnosis of rhino-orbito-cerebral mycosis caused by Aspergillus spp.

Keywords: Aspergillosis; COVID-19; Rhino-orbito-cerebral mycosis; Serum galactomannan.

MeSH terms

  • Adult
  • Aged
  • Aspergillosis / diagnosis
  • Aspergillus / isolation & purification
  • COVID-19* / blood
  • COVID-19* / complications
  • COVID-19* / diagnosis
  • Female
  • Galactose* / analogs & derivatives*
  • Humans
  • Male
  • Mannans* / blood
  • Middle Aged
  • SARS-CoV-2

Substances

  • galactomannan
  • Mannans
  • Galactose